a pattern ive noticed usually remdesivir first maybe next

New Post Public Reply Private Reply Replies (0) Message Board
crazyjogger925 nmbr1stckpckr #110210
739
a pattern ive noticed usually remdesivir first maybe next tocilizumab followed by a few others usually for severe cases.then when all else fails maybe the patient gets LL IF LUCKY ?


check out the trodelvy pricing immunomedics set up for tnbc back in april 2020 and pretty much in line with the gilead pricing today.makes leronlimab the bargain of the century.imo

Immunomedics Inc. shares (NASDAQ:IMMU) were trading at $26.96, up $4.99, or 22%, on the approval yesterday of the antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) to treat metastatic triple-negative breast cancer. Trodelvy, to be launched soon, was cleared for patients who have undergone at least two prior therapies. Morris Plains, N.J.-based Immunomedics set the wholesale acquisition cost for a single-use 180-mg vial at $2,012, which equates to $16,096 per 21-day cycle for a 70-kg person. Officials outlined marketing plans during a conference call with investor

https://www.goodrx.com/trodelvy

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Winning Strategies for Sales Teams: Ebsta’s Insights Unveiled

Updated Category News Views 128

Winning Strategies for Sales Teams: Ebsta’s Insights Unveiled In today's competitive landscape, sales teams are continually seeking ways to outperform their competition. A recent comprehensive report from the revenue intelligence company Ebsta highlights groundbreaking findings on what sets top-performing sales teams apart. This study reveals that effective...

Continue Reading
Investigation into Cardlytics: What Investors Need to Know

Updated Category News Views 264

Understanding the Investigation into Cardlytics Faruqi & Faruqi, LLP, a recognized leader in securities litigation, is actively investigating potential claims on behalf of investors who may have suffered losses while investing in Cardlytics, Inc. (NASDAQ: CDLX). This inquiry aims to clarify the missteps taken by the company and to uphold the rights of its shareholders....

Continue Reading
GIGABYTE Launches Innovative QD-OLED Monitors Redefining Gaming

Updated Category News Views 403

GIGABYTE Introduces Cutting-Edge QD-OLED Monitors GIGABYTE, renowned as a leader in computer technology, has unveiled two revolutionary QD-OLED monitors that are set to transform the gaming and professional display landscape. The AORUS FO27Q5P and GIGABYTE MO27U2 are equipped with extraordinary features that provide unmatchable clarity and swift performance, catering to...

Continue Reading
Key Financial Insights from OPEC and Fed Speech Planned

Updated Category News Views 65

Analyzing Upcoming Financial Events Traders are gearing up for an important day in the financial markets. The focus is set on crucial reports and speeches that can significantly influence market behavior. Key among these events are the OPEC Monthly Report and the anticipated speech from Federal Reserve Governor Christopher Waller. What to Expect from the OPEC Monthly...

Continue Reading
Vestis Corporation Investors Urged to Take Action Now

Updated Category News Views 148

Important Announcement for Vestis Corporation Investors If you've invested in Vestis Corporation (NYSE: VSTS), it's crucial to stay informed about the potential legal actions unfolding due to significant allegations about the company's operations. Why Legal Counsel is Essential Under a contingency fee arrangement, investors who purchased securities between May 2, 2024,...

Continue Reading